Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 15/20 | 0.98 |
| ▸ | EDNRB | P24530 | 11/20 | 0.98 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-754142 SCHEMBL29551244 | 0.99 | EDNRA (1.00) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL4193035 | 0.99 | EDNRA (1.00) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL4202655 | 0.98 | EDNRA (0.98) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL23499204 | 0.94 | EDNRA (0.89) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7337876 | 0.94 | EDNRA (0.89) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7341739 | 0.93 | EDNRA (0.88) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7332944 | 0.93 | EDNRA (0.88) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7339397 | 0.93 | EDNRA (0.88) | EDNRAEDNRBAGTR1AGTR2 | |
| SCHEMBL7329183 | 0.92 | EDNRA (0.86) | EDNRAEDNRBAGTR1AGTR2 | |
| L-754142 SCHEMBL4202652 | 0.92 | EDNRA (0.86) | EDNRAEDNRBAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT SINGH (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021118826-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT (US) | 2021-06-17 | — | — | WO | disclosed |
| US-6395741-B1 | SENSITIVITY TO ENDOTHELIN; UROGENITAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| EP-1066831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISORDER | TANABE SEIYAKU CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | AGTR2, AGTR1, EDNRA | EDNRA 3/4885EDNRB 4/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.